Group 1 - The stock price of Nearshore Protein increased by 5.22% to 43.56 CNY per share, with a trading volume of 23.6 million CNY and a turnover rate of 1.71%, resulting in a total market capitalization of 3.057 billion CNY [1] - Nearshore Protein Technology Co., Ltd. was established on September 7, 2009, and went public on September 29, 2022. The company specializes in the research, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, along with providing related technical services [1] - The revenue composition of Nearshore Protein includes: target and factor proteins (58.04%), enzymes and reagents (25.63%), CRO services (11.87%), recombinant antibodies (2.67%), and other (1.79%) [1] Group 2 - ICBC Credit Suisse Fund's ICBC Strategic Transformation Stock A (000991) entered the top ten circulating shareholders of Nearshore Protein, holding 338,800 shares, which is 1.04% of the circulating shares, with an estimated floating profit of approximately 731,700 CNY [2] - ICBC Strategic Transformation Stock A was established on February 16, 2015, with a latest scale of 2.171 billion CNY. The fund has achieved a year-to-date return of 13.86% and a one-year return of 28.15% [2] Group 3 - The fund manager of ICBC Strategic Transformation Stock A is Du Yang, who has been in the position for 10 years and 226 days, managing a total fund size of 10.739 billion CNY, with the best fund return during his tenure being 290% and the worst being -37.97% [3]

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-038 苏州近岸蛋白质科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 12 日 （二） 股东大会召开的地点：苏州市吴江区文苑路 88 号东恒盛国际大酒店五楼 姑苏厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 48 | | --- | --- | | 普通股股东人数 | 48 | | 2、出席会议的股东所持有的表决权数量 | 47,717,078 | | 普通股股东所持有表决权数量 | 47,717,078 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 68.3909 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 68.3909 | （四） 表 ...

国浩律师（上海）事务所 关 于 苏州近岸蛋白质科技股份有限公司 2025 年第一次临时股东大会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28th Floor, Suhe Centre, No.99 West Shanxi Road, Shanghai 200085, China 电话/Tel:+86 21 5234 1668 传真/Fax:+86 21 5243 3320 网址/Website: http://www.grandall.com.cn 2025 年 9 月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 致：苏州近岸蛋白质科技股份有限公司 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）2025 年第一次临时 股东大会于 2025 年 9 月 12 日召开。国浩律师（上海）事务所（以下简称"本 所"）经公司聘请，委派律师出席现场会议，见证公司 2025 年第一次临时股东 大会（以下简称"本次股东大会"）。 本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）等法律、法规及《上市公司股东会 ...

Core Viewpoint - The report outlines the continuous supervision and compliance of Suzhou Nearshore Protein Technology Co., Ltd. after its IPO on the Sci-Tech Innovation Board, emphasizing the company's adherence to regulations and its operational performance despite financial losses. Continuous Supervision Work - The sponsor has established a robust continuous supervision system and work plan for the company, ensuring compliance with relevant regulations and effective communication [1][2] - The sponsor conducted regular visits, due diligence, and checks to monitor the company's operations and compliance with laws and regulations [1][2] - Throughout the supervision period, the company did not encounter any violations or breaches of commitments that required public disclosure [1][2] Financial Performance - For the first half of 2025, the company reported revenue of approximately 72.09 million, a year-on-year increase of 20.85% [8] - The net loss attributable to shareholders was approximately 24.22 million, with a net profit excluding non-recurring items of about -26.68 million [8] - The company’s cash flow from operating activities was -14.08 million, indicating a significant decline compared to the previous year [8] Core Competitiveness - The company has developed seven comprehensive technology platforms and 23 core technologies, which are crucial for maintaining its market competitiveness [5][9] - The company emphasizes the importance of protecting its core technologies to prevent leakage, which could adversely affect its operations [5][9] - A skilled and stable technical team is essential for sustaining technological leadership and core competitiveness [5][9] Industry Risks - The RNA vaccine and drug industry is still maturing, with uncertainties in demand for mRNA raw materials and reagents in various applications [7][8] - The company faces intense competition from both domestic and international players, which could impact its market position and profitability [6][7] Research and Development - The company invested approximately 26.1 million in R&D in the first half of 2025, accounting for 36.21% of its revenue, reflecting a slight decrease from the previous year [16] - As of June 30, 2025, the company holds 38 invention patents, 22 utility model patents, and 18 software copyrights, indicating a strong focus on innovation [16] Use of Raised Funds - The company raised approximately 186.30 million through its IPO, with 174.22 million remaining after deducting issuance costs, and has complied with regulations regarding the use of these funds [17][18]

民生证券股份有限公司 关于苏州近岸蛋白质科技股份有限公司 2025 年半年度持续督导跟踪报告 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为苏州 近岸蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"）首次公开发 行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》以及《科创板上市公司持续监管办法（试行）》 等有关法律法规和规范性文件的要求，负责近岸蛋白上市后的持续督导工作，并 出具本持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 本持续督导期间，保荐机构已建立健全 | | 1 | 度，并针对具体的持续督导工作制定相 | 并有效执行了持续督导制度，并制定了 | | | 应的工作计划 | 相应的工作计划 | | | 根据中国证监会相关规定，在持续督导 | 本持续督导期间，保荐机构已与近岸蛋 | | | 工作开始前，与上市公司或相关当事人 | | | 2 | 签署持续督导协议，明确双方在持续督 | 白签订承销及保荐协议，该协议明确了 | ...

Core Viewpoint - The company is convening its first extraordinary general meeting of shareholders in 2025 to discuss key proposals, including the use of excess raised funds to supplement working capital and the reappointment of an accounting firm for financial auditing [6][8]. Group 1: Meeting Procedures - The meeting will follow a structured agenda, allowing shareholders to exercise their rights, including speaking, questioning, and voting [2][3]. - Shareholders must register and present necessary identification documents to participate in the meeting [1][2]. - Voting will be conducted through both on-site and online methods, with specific time frames for each [4][6]. Group 2: Proposals - Proposal 1 involves using CNY 72 million (approximately USD 10.1 million) of excess raised funds to permanently supplement working capital, which represents 29.73% of the total excess funds raised of CNY 242.2 million (approximately USD 34.1 million) [6][8]. - Proposal 2 seeks to reappoint Rongcheng Accounting Firm for the 2025 financial audit, with an audit fee of CNY 700,000 (approximately USD 98,000), maintaining the same fee as the previous year [8][12].

苏州近岸蛋白质科技股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688137 证券简称：近岸蛋白 苏州近岸蛋白质科技股份有限公司 2025 年第一次临时股东大会 会议资料 2025 年 9 月 苏州近岸蛋白质科技股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 | 年第一次临时股东大会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 | 3 | | | 议案一 | 关于使用部分超募资金永久补充流动资金的议案 5 | | | 议案二 关于续聘会计师事务所的议案 | 6 | 苏州近岸蛋白质科技股份有限公司 2025 年第一次临时股东大会会议资料 苏州近岸蛋白质科技股份有限公司 七、主持人可安排公司董事和高级管理人员回答股东所提问题，对于可能将 泄露公司商业秘密及/或内幕信息，损害公司、股东共同利益的提问，主持人或 其指定的有关人员有权拒绝回答。 1 2025 年第一次临时股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权利， 根据《公司法》、中国证监会《上市公司股东大会规则》和公 ...

公司于 2024 年 9 月 26 日召开第二届董事会第六次临时会议，并于 2024 年 10 月 15 日召开 2024 年第三次临时股东大会，审议通过了《关于稳定股价措施暨以 集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海证券 交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股） 股票。回购股份将用于依法注销、减少注册资本，回购价格不超过 30.68 元/股（含）， 回购资金总额不低于人民币 1,000 万元（含），不超过人民币 2,000 万元（含）， 回购期限自公司股东大会审议通过本次回购方案之日起 12 个月内。 具 体 内 容 详 见 公 司 于 2024 年 9 月 28 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《苏州近岸蛋白质科技股份有限公司关于稳定股价措 施暨以集中竞价方式回购股份方案的公告》（公告编号：2024-041）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间，应当在每个月的前 3 个交 易日内公告截 ...

Core Viewpoint - Nearshore Protein (688137.SH) has announced that as of August 31, 2025, the company has not yet initiated a stock buyback program, but it plans to implement this buyback based on market conditions in the future [1] Summary by Relevant Categories - Company Actions - The company has not commenced any stock repurchase activities as of the specified date [1] - Future buyback plans will be contingent upon market conditions [1]